Category Archives: Molecular Medicine

Stem Cells and the Future of Medicine - Larry Goldstein, Ph.D. at TEDxAmericasFinestCity
Dr. Goldstein is a Professor of Cellular and Molecular Medicine at the University of California, San Diego, School of Medicine. He received his BA degree in biology and genetics at UCSD and his Ph.D. degree in genetics from the University of Washington, Seattle. He did his postdoctoral work at the University of Colorado at Boulder and the Massachusetts Institute of Technology. Prior to moving to UCSD, he was Professor of Cellular and Developmental Biology at Harvard University.From:TEDxTalksViews:242 13ratingsTime:16:15More inScience Technology

Read this article:
Stem Cells and the Future of Medicine - Larry Goldstein, Ph.D. at TEDxAmericasFinestCity - Video

22 Molecular Medicine mdash;Cloning and Stem Cells
From:jeffrey727Views:2 0ratingsTime:30:56More inEducation

Excerpt from:
22 Molecular Medicine—Cloning and Stem Cells - Video

London, October 1 (ANI): Though the two proteins previously found to contribute to ALS have divergent roles, a common pathway links them.

This is according to a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine.

The discovery reveals a small set of target genes that could be used to measure the health of motor neurons, and provides a useful tool for development of new pharmaceuticals to treat the devastating disorder, which currently has no treatment or cure.

ALS, also known as Lou Gehrig's disease, is an adult-onset neurodegenerative disorder characterized by premature degeneration of motor neurons, resulting in a progressive, fatal paralysis in patients.

The two proteins that contribute to the disease - FUS/TLS and TDP-43 - bind to ribonucleic acid (RNA), intermediate molecules that translate genetic information from DNA to proteins.

In normal cells, both TDP-43 and FUS/TLS are found in the nucleus where they help maintain proper levels of RNA. In the majority of ALS patients, however, these proteins instead accumulate in the cell's cytoplasm - the liquid that separates the nucleus from the outer membrane, and thus are excluded from the nucleus, which prevents them from performing their normal duties.

Since the proteins are in the wrong location in the cell, they are unable to perform their normal function, according to the study's lead authors, Kasey R. Hutt, Clotilde Lagier-Tourenne and Magdalini Polymenidou.

"In diseased motor neurons where TDP-43 is cleared from the nucleus and forms cytoplasmic aggregates," the researchers wrote, "we saw lower protein levels of three genes regulated by TDP-43 and FUS/TLS. We predicted that this, based on our mouse studies, and found the same results in neurons derived from human embryonic stem cells."

In 2011, this team of UC San Diego scientists discovered that more than one-third of the genes in the brains of mice are direct targets of TDP-43, affecting the functions of these genes. In the new study, they compared the impact of the FUS/TLS protein to that of TDP-43, hoping to find a large target overlap.

"Surprisingly, instead we saw a relatively small overlap, and the common RNA targets genes contained exceptionally long introns, or non-coding segments. The set is comprised of genes that are important for synapse function," said principal investigator Gene Yeo, PhD, assistant professor in the Department of Cellular and Molecular Medicine and the Institute for Genomic Medicine at UC San Diego and a visiting professor at the Molecular Engineering Laboratory in Singapore.

See the article here:
Culprits behind ALS and dementia share common pathway

Public release date: 30-Sep-2012 [ | E-mail | Share ]

Contact: Debra Kain ddkain@ucsd.edu 619-543-6163 University of California - San Diego

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

The discovery reveals a small set of target genes that could be used to measure the health of motor neurons, and provides a useful tool for development of new pharmaceuticals to treat the devastating disorder, which currently has no treatment or cure.

Funded in part by the National Institutes of Health and the California Institute for Regenerative Medicine (CIRM), the study will be published in the advance online edition of Nature Neuroscience on September 30.

ALS is an adult-onset neurodegenerative disorder characterized by premature degeneration of motor neurons, resulting in a progressive, fatal paralysis in patients.

The two proteins that contribute to the disease FUS/TLS and TDP-43 bind to ribonucleic acid (RNA), intermediate molecules that translate genetic information from DNA to proteins. In normal cells, both TDP-43 and FUS/TLS are found in the nucleus where they help maintain proper levels of RNA. In the majority of ALS patients, however, these proteins instead accumulate in the cell's cytoplasm the liquid that separates the nucleus from the outer membrane, and thus are excluded from the nucleus, which prevents them from performing their normal duties.

Since the proteins are in the wrong location in the cell, they are unable to perform their normal function, according to the study's lead authors, Kasey R. Hutt, Clotilde Lagier-Tourenne and Magdalini Polymenidou. "In diseased motor neurons where TDP-43 is cleared from the nucleus and forms cytoplasmic aggregates," the authors wrote, "we saw lower protein levels of three genes regulated by TDP-43 and FUS/TLS. We predicted that this, based on our mouse studies, and found the same results in neurons derived from human embryonic stem cells."

In 2011, this team of UC San Diego scientists discovered that more than one-third of the genes in the brains of mice are direct targets of TDP-43, affecting the functions of these genes. In the new study, they compared the impact of the FUS/TLS protein to that of TDP-43, hoping to find a large target overlap.

"Surprisingly, instead we saw a relatively small overlap, and the common RNA targets genes contained exceptionally long introns, or non-coding segments. The set is comprised of genes that are important for synapse function," said principal investigator Gene Yeo, PhD, assistant professor in the Department of Cellular and Molecular Medicine and the Institute for Genomic Medicine at UC San Diego and a visiting professor at the Molecular Engineering Laboratory in Singapore. "Loss of this common overlapping set of genes is evidence of a common pathway that appears to contribute to motor neuron degeneration."

See the article here:
Common RNA pathway found in ALS and dementia

WASHINGTON, July 13, 2012 /PRNewswire-iReach/ -- Science Translational Medicine, the newest journal from the American Association for the Advancement of Science (AAAS), and the Days of Molecular Medicine Global Foundation (DMM GF) announced today the launch of Days of Molecular Medicine 2012 "The Translational Science of Rare Diseases: From Rare to Care," a three-day meeting which will be held in Vienna, Austria from October 8 through October 10, 2012.

Taking place at the Palais de Lichtenstein, and featuring an international roster of academic, industrial and government scientists, headlined by Nobel Laureate Dr. Eric Kandel, the meeting will cover how new technologies are providing fresh insights into the causes of rare diseases and ways forward for developing new treatments.

Featured topics include a new targeted therapy for cystic fibrosis, exon skipping for treating muscular dystrophy, gene therapy for SCID and hemophilia, tailoring treatments with genomics, and embryonic stem cell therapy for treating retinal diseases. Joining Science Translational Medicine, AAAS and the DMM Global Foundation in launching Days of Molecular Medicine 2012 are the following co-organizers: the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Ludwig Maximilians University Munich, the Karolinska Institute, and Fondation Ipsen.

Days of Molecular Medicine 2012 is also made possible through the generous sponsorship of Boehringer Ingleheim, Inc.

"The Days of Molecular Medicine 2012 conference will discuss the many different causes of rare diseases," says Orla Smith, Managing Editor of Science Translational Medicine, "and the diverse roster of speakers will provide fresh insights into how we can develop effective new treatments."

"From cystic fibrosis to hemophilia, there are a number of diseases that, while classified as "rare", afflict a significant number of people worldwide," says Ken Chien, DMM Global Foundation Director. "With enough attention from the research community, and the application of cutting-edge technology, we can start to bring much needed relief to patients and their families. That's what DMM 2012 is all about."

"Rare diseases often come with unspeakable suffering where children are mainly affected. It is a matter of great importance to me to support every effort to share knowledge and develop new ideas, which will hopefully turn into added value for the patients, " says Dr. Josef Penninger of the IMBA. "Therefore, it is a special honor for me to host this year's Days of Molecular Medicine Meeting here in Vienna on this very topic."

For further information and to register for the meeting visit dmm.aaas.org.

About AAAS/Science Translational Medicine The American Association for the Advancement of Science (AAAS), the world's largest general scientific society, is the publisher of the journal Science (www.sciencemag.org) and the sister journals Science Translational Medicine (www.sciencetranslationalmedicine.org) and Science Signaling (www.sciencesignaling.org). The goal of Science Translational Medicine, launched in October 2009, is to promote human health by providing a forum for communicating the latest biomedical research findings from all established and emerging disciplines relevant to medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. Science Translational Medicine seeks to publish articles that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of this knowledge into new ways to prevent, diagnose and treat human disease.

About DMM Global Foundation The DMM Global Foundation is dedicated to promoting the career pathways for physician scientists. Over the past decade, the members of the Foundation have worked to initiate and establish DMM as one of the leading scientific forums to champion the importance of translational science and medicine via partnerships with leading international institutions, foundations, and scientific publishing groups. The Foundation is proud to be a co organizer and sponsor of DMM 2012.

Read this article:
Science Translational Medicine and the DMM Global Foundation Announce Days of Molecular Medicine 2012 "The ...

Public release date: 24-Apr-2012 [ | E-mail | Share ]

Contact: Dr Boris Kovacic Boris.Kovacic@vetmeduni.ac.at 43-125-077-5622 University of Veterinary Medicine -- Vienna

Although people generally talk about "cancer", it is clear that the disease occurs in a bewildering variety of forms. Even single groups of cancers, such as those of the white blood cells, may show widely differing properties. How do the various cancers arise and what factors determine their progression? Clues to these two issues, at least for leukaemias, have now been provided by Boris Kovacic and colleagues at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna). The results are published in the current issue of the journal EMBO Molecular Medicine and have extremely important consequences for the treatment of a particularly aggressive type of leukaemia.

It is well known that many types of cancer arise as a result of a mutation within a cell and prevailing wisdom has held that the stage of differentiation of this cell determines exactly what form of cancer develops. For example, it was believed that so-called chronic myeloid leukaemia or CML arises from bone marrow stem cells, while a different type of leukaemia, known as B-cell acute lymphoid leukaemia or B-ALL, results from B-cell precursors. This belief has been spectacularly refuted by the latest results from Boris Kovacic and colleagues in the Vetmeduni Vienna's institutes of Animal Breeding and Genetics and of Pharmacology and Toxicology.

The researchers have now shown that both CML and B-ALL arise from the most primordial kind of blood cell (long-term haematopoietic stem cells), although the pathways by which the diseases progress are different. The usual causes of CML and B-ALL are two highly related versions of the same oncogene, BCR/ABL. If the primordial blood cells are transformed or made potentially cancerous by a particular version of BCR/ABL, for technical reasons termed BCR/ABLp210, the result is chronic myeloid leukaemia or CML. The long-term haematopoietic stem cells remain and act as the dreaded cancer stem cells, or CSCs, which ensure that the disease persists. Curing chronic myeloid leukaemia requires the complete elimination of the CSCs. However, if the long-term haematopoietic stem cells are transformed by a related version of BCR/ABL, BCR/ABLp185, the result is a highly aggressive form of leukaemia, B-ALL. The finding that B-ALL actually originates from the same stem cells as CML was both unexpected and highly provocative.

Kovacic and colleagues have shown further that B-ALL only develops if the transformed stem cell is exposed to a particular growth factor, interleukin-7. If interleukin-7 is present (it usually is), the transformed long-term haematopoietic stem cells undergo a differentiation step to CSCs, which in this case correspond to pro-B cells. If interleukin-7 is absent during the initial phase of transformation, B-ALL cannot develop.

In other words, two distinct types of cell are involved in leukaemia development, the primordial cells (also termed the cells of origin of cancer) and the cancer stem cells that cause the disease to progress. Unless the CSCs are eliminated, fresh cancer cells can arise at any time and the leukaemia will recur. The problem is that current leukaemia therapies are not designed to target CSCs. The primordial CSCs in CML are highly quiescent and thus difficult to target. In contrast, the CSCs in B-ALL are abundant and have a high turnover rate, which makes them susceptible to treatment. Treatment of B-ALL may thus succeed in eliminating most CSCs but if even a single cell remains intact it is likely that the patient will relapse, possibly with an even more aggressive form of leukaemia. "A therapy that targets the bulk of tumour cells will not work," as Kovacic succinctly summarizes his results. "To treat B-ALL successfully it will be necessary for us to learn much more about the development of the disease. A combined therapy is required, so future work should aim at developing drugs that target the long-term haematopoietic stem cells from which B-ALL is derived."

###

The paper "Diverging fates of cells of origin in acute and chronic leukemia" by Boris Kovacic, Andrea Hoelbl, Gabriele Litos, Memetcan Alacakaptan, Christian Schuster, Katrin M. Fischhuber, Marc A. Kerenyi, Gabriele Stengl, Richard Moriggl, Veronika Sexl and the late Hartmut Beug is published in the current issue of the journal "EMBO Molecular Medicine" (2012, Vol. 4 pp. 283-297).

The work was initiated at the Research Institute of Molecular Pathology (IMP) and was performed together with groups at the Medical University of Vienna and the Ludwig Boltzmann Institute for Cancer Research in Vienna.

Link:
Leukaemia cells have a remembrance of things past

Needham, MA (PRWEB) February 17, 2012

Cambridge Healthtech Institute announces 47 exhibitors & sponsors to showcase new products at the 19th Molecular Medicine Tri-Conference, taking place February 19-23, at the Moscone North Convention Center, San Francisco, CA. The Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating the entire spectrum of drug development.

The Molecular Medicine Tri-Conference has experienced seven straight years of attendee growth, while maintaining a high quality audience. This year’s event is on track to be another successful event. Spanning three days, the meeting is built around 5 scientific channels, encompassing 13 conferences, providing attendees more learning opportunities than ever before.

The 2012 event includes the New Product Showcase, where 47 companies will showcase their new products to event delegates.

New Products Include:
Abnova        
Captor™- Captor™ is a label-free microfiltration system for isolation, enumeration, and retrieval of circulating tumor cells (CTCs) for translational research, preclinical and clinical studies.

Collaborative Drug Discovery (CDD)
Collaborative Drug Discovery (CDD) Vault® for molecular registration and SAR is:
Lightweight for budget-sensitive labs
Collaborative to scale
Are you a curious scientist?
Explore CDD - Booth #316

ELSEVIER        
Target Insights - Target Insights is an online decision support tool in the drug discovery space. It enables users to identify, prioritize and validate biological targets more quickly and with less risk.

Ingenuity® Systems    
Ingenuity ® iReport ™ - Ingenuity ® iReport ™ is a highly visual, interactive report that rapidly translates a single expression dataset into actionable biological insights through combined statistical and biological analysis.

MetanomicsHealth            
MxPTM-Energy- MetanomicsHealth combines state-of-the-art metabolite profiling, which enables the analysis of endogenous and xenobiotic metabolites produced during cellular metabolism, with innovative bioinformatics and data mining systems to gain insight into the mechanistic basis of diseases and determine responses to drugs, nutritional or toxic effects. MetanomicsHealth’s targeted energy platform is used to describe physiological conditions affecting the energy status of a cell as well as cell proliferation or apoptosis, processes of high relevance in the area of oncology.

REMEDY Informatics    
InvestigateTM - The Translational Informatics System - InvestigateTM accelerates translational research with 360-degree integration of bench-to-bedside data types, intuitive visual analytics for pattern recognition, a collaborative and extensible ontology, and LIMS, ELN, biospecimen, and clinical registry management.
SurModics
SurModics® Assay Diluent (Protein-Free) & TMB Enhanced One Component HRP Membrane Substrate & StabilBlot™ Blocker Family
SurModics® Assay Diluent (Protein-Free) - SurModics assay diluent was developed to reduce matrix interference in samples including heterophilic antibodies, such as HAMA (human anti-mouse antibody) and RF (rheumatoid factor). Data indicate that it significantly increases to signal-to-noise ratios and provides a protein-free alternative.
TMB Enhanced One Component HRP Membrane Substrate – SurModics TMB Enhanced One Component HRP Membrane Substrate is a ready to use solution containing 3,3’, 5,5’-tetramethylbenzidine in a mildly acidic buffer. The substrate reacts with peroxidase to form an insoluble permanent dark blue/purple color on the membrane or surface to which it is applied. This enhanced formulation extends the dynamic range of detection, especially at higher concentrations of peroxidase where other substrates may exhibit loss of signal due to washout effects.
StabilBlot™ Blocker Family - The StabilBlot™ Blocker Family is formulated to minimize background and enhance sensitivity in blotting applications. Choose from four formulations to customize based on your assay requirements: Protein-Free, BSA, Casein, and Milk.
TECAN            
HP D300 Digital Dispenser - Tecan introduces the HP D300 Digital Dispenser. This benchtop instrument dispenses picoliter to microliter sample volumes to create dose response curves. IC50 determinations can be shortened from hours or days to just minutes.

Abbott Molecular                                    
Vysis ALK Break Apart FISH Probe Kit - The Vysis ALK Break Apart FISH Probe Kit is a qualitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin?fixed paraffin?embedded (FFPE) non?small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with Xalkori® (crizotinib). FDA Approved
c-Kit RUO Kit A Sequencing Assay - The c?Kit RUO* Kit A is a Research Use Only in vitro assay for determining the mutations in exons 11, 13, 17, and 18 of the human c?Kit gene. *Not for use in diagnostic procedures.

ABS Inc.                     
Advanced Mycoplasma Testing Service - ABS is providing a new testing service for the detection of Mycoplasma contamination in cell cultures that is a new Gold Standard for objective unambiguous results.

Advanced Cell Diagnostics
RNAscope 2.0 - RNAscope is a breakthrough RNA in situ hybridization (ISH) method that enables routine detection and in situ visualization of virtually any gene at single-molecule sensitivity in formalin-fixed paraffin-embedded (FFPE) tissue.

Ambry Genetics                
CLIA EXOME – Ambry Genetics is the first to provide researchers with CLIA exome sequencing services. Our service can be used for biomarker discovery, tumor analysis, pharmacogenomics response and Mendelian disease gene discovery.
AXXIN                
Axxin T16 - Isothermal Instrument - Axxin’s advanced isothermal instrument enables the next generation of diagnostic DNA/RNA amplification in a compact, low cost, and sensitive instrument suitable for point of care diagnostic applications. Configured for up to 16 tubes simultaneously and 3 fluorophores.
BioGenex                    
Xmatrix Infinity - Fully automated and flexible instrument capable of performing IHC, ISH, FISH, CISH, IF and co-detection and multiplexing of protein and nucleic acid biomarkers. Double Stain Detection System - BioGenex double staining detection system is a biotin-free, super sensitive system, which provides a robust detection for visualizing multiple antigens simultaneously on the same tissue sample. It can be used with mouse and rabbit antibodies. MicroRNA in situ detection kits - Using fluorescein labeled probe, BioGenex microRNA in situ detection kits yield exceptional sensitivity and specificity enabling visualization of miRNA in difficult FFPE samples by either chromogenic or fluorescent detection systems.

Bioneer                    
ExiStation™ Molecular Diagnostics system - ExiStation™ is able to process on average 36 samples/hour, is able to handle up to 6 different types of clinical samples within a single run and is a pipetting-free system.

BioScale, Inc.                
ViBE Protein Analysis Workstation – AMMP Phospho-Protein Assay - BioScale’s ViBE Protein Analysis Workstation and AMMP assays significantly improve sensitivity, accelerate the time-to-results and reduce assay development time for phospho-protein analysis including pP38, pERK1/2, pJNK, pAKT, pALK, & MEK.
BioView USA, Inc.                 
Circulating Tumor Cell System - BioView’s newly developed Circulating Tumor Cell application provides automatic scanning for the detection, capture, enumeration and retrieval of cellular and marker characteristics of any type of enriched sample hybridized with any combination of fluorescent antibodies.
Complete Genomics                
Complete Genomics Cancer Sequencing Service – The Cancer Sequencing Service provides whole human genome sequencing of cancer pairs or trios, delivering somatic and germline variations including SNP’s, indels, CNV’s, structural variations, and mobile element insertions.
Computype                
Tube Pro Labeling System – Label Print – and – Apply System for a wide variety of tubes and vials, including eppendorf tubes. For more information, please visit us at Booth#220.
Covance                    
Covance Discovery and Translational Services - Covance Discovery and Translational Services provides broad capabilities and in-depth scientific and technical expertise to enable faster go/no go decisions. Our scientific teams have industry experience supporting drug discovery and development and work in facilities purpose built by pharmaceutical companies for drug development. Whether you need a single study or a comprehensive discovery and translational services program, Covance offers extensive resources and industry expertise to help you solve your toughest development challenges.
Crown Bioscience Inc.            
HuPrime®2.0 - CrownBio’s proven commitment to building broader, deeper, smarter PDX models, HuPrime®2.0 is the next generation of world’s largest collection genetically characterized human patient tumorgraft invivo models. Check us out today!
Cyagen                
Vector Builder- Vector Builder is a versatile online tool in which you can design your own experimental DNA vectors! Then save time and have us custom build them at a highly competitive price.
Cytel Inc                            
Adaptive Clinical Trials for Oncology – Cytel Inc is a leading provider of clinical trial services and specialized statistical software for biopharmaceutical, medical device, academic and government research. markets.        
Fluxion Biosciences                        
IsoFlux™ Rare Cell Access System - The IsoFlux™ Rare Cell Access System provides a new direction for clinical research. It isolates rare cells from a wide range of clinical samples and makes them available for further analysis using the proprietary CellSpot™ Technology.
fortéBIO                            
ForteBio introduces BLItz, a personal system for micro-volume, label-free analysis - BLItz™ tests for protein presence, does protein quantitation and measures binding kinetics effortlessly in just a drop of sample. Cleverly priced under $20K. Drop. Read. Done. Genius! Try BLItz at Booth 500.

General Atomics, Nirvana Division                
Nirvana Storage Resource Broker (SRB)- Nirvana SRB federates complex legacy environments, providing storage virtualization and metadata management solutions for high-value unstructured data. A unified operations view simplifies migrations, synchronizations, and data management tasks.

Jubilant Biosys Ltd.                    
HTS and Ion Channel Screening - Jubilant’s added expertise in Electrophysiology, High Throughput Screening and In Vitro Biology, enabling Ion channel target prosecution in addition to GPCR’s and Kinases leverages expertize across global discovery centers.

Linguamatics                
I2E MANAGED SERVICES - I2E Managed Services is a cloud-based text mining service tailored for each customer’s needs for content and vocabularies from both internal and external sources.
Lonza                    
NodeSensor™ Assays – are made up of two interacting proteins co-expressed in a human cell line. They enable sensitive and high content detection and measurement, using inherently proteins as reporters.
Norgen Biotek                
RNA Extraction Services- Norgen offers RNA Extraction services from all types of samples at a reasonable price. Have our specialists isolate RNA (including microRNA) from your samples, guaranteeing total RNA of the utmost quality and yield.

Oxford Gene Technology            
NGS – Targeted Sequencing Services - Our comprehensive targeted sequencing service takes you all the way from project design to high-quality, filtered results. Unique and complimentary analysis software provides fast and intuitive access to prioritized results. For more information please contact: OGT Diagnostic Biomarkers, Begbroke Science Park, Sandy Lane, Yarnton, Oxford, OX51PF, T: 0044 (0) 1865 856826, F: 0044 (0) 1865 848684, E: products@ogt.co.uk

Omni International – The Homogenizer Company    
Omni LH96 Automated Homogenizer Workstation - The Omni LH96: homogenize, dispense liquids, pipette, weigh, and eliminate cross-contamination - all with one space-saving automated device. What used to take hours can now be completed in minutes!
Optibrium Ltd                
StarDrop - StarDrop is a suite of software for guiding decisions in drug discovery, helping project teams identify high-quality compounds, fast.
Parthys Reverse Informatics             
Periodic Technology Alerts for Drug Targets - Our alert reports are empowered by synonyms dictionary, which enables us to supply the latest patent applications & patents on your drug target of interest at intervals determined by you!

Platform Computing, an IBM Company            
Platform Symphony MapReduce - Platform Symphony MapReduce is a best-of-breed, enterprise-class distributed runtime engine for MapReduce applications. While 100% compatible with open source Hadoop, Platform Symphony MapReduce provides unique capabilities such as a mixed workload support, dynamic resource sharing and high availability of HDFS NameNode to ensure success deployment of Hadoop applications into production environment. With Platform Symphony MapReduce, organizations benefit from faster performance, high resource utilization (75% sustained level), improved reliability and manageability with their IT infrastructure.

Randox Laboratories                
KRAS, BRAF and PIK3CA Biochip Arrays – Randox announces the launch of the world’s first Biochip Array capable of detecting 20 mutations across KRAS, BRAF and PIK3CA, utilizing a rapid, sensitive, single tube, multiplex PCR.

Rubicon Genomics            
NovaPLEX Prep Kits - Rubicon has introduced its NovaPLEX™ Prep Kit family, including ThruPLEX™-FD and PicoPLEX™-SC NGS prep kits for fragmented DNA and single cells, as well as OmniPLEX™ preps for diagnostic microarrays.    

SARmont LLC                
Medicinal Chemistry Design and Lead Optimization Services – Design services led by Dr. John Talley, CSO, the inventor of Celebrex and seven other FDA approved drugs. Early stage design and lead optimization services – all IP is retained by the client. Cost efficient compound synthesis via our strategic CRO partner in India, Escientia.     

Sequenom                    
iPLEX® ADME PGx panel - iPLEX® ADME PGx panel empowers your screening and validation of genotypes associated with drug metabolism. Simultaneously analyze 192 mutations in 36 pharmacogenetically relevant genes and identify SNPs, INDELS, and CNVs.

Silicon Biosystems, Inc.            
Silicon Biosystems’ DEPArray™ Platform, utilizing image-based cell selection, is ideally suited to isolate single cells without contact, from enriched blood samples, such as CTCs and Stem Cells, with 100% purity.

SomaLogic            
SOMAscan - SomaLogic’s unique SOMAscan™ technology protein biomarker discovery for target discovery and validation, clinical and companion diagnostic development, drug discovery and development, clinical trial design and execution, drug response, and understanding disease biology.

Sony DADC                
SiMoA - Production of the SiMoA consumable is very similar to the manufacturing techniques used for DVD optical discs. Two injection molded discs with microstructures are bonded by laser welding to achieve a laminated final product.

Spry Inc.                    
Agile Analytics - Agile Analytics combines semantic technologies, agile development, and stakeholder engagement tactics to quickly develop data-rich gadgets capable of supporting interoperability analysis, policy compliance, data governance, investment analysis, and portfolio management.

The Jackson Laboratory            
Diversity Outbred Mice (J:DO, Strain No. 009376) - The Diversity Outbred mouse is a new heterogeneous, highly diverse resource designed for complex trait analysis, toxicology/pharmacogenomic screens, compound evaluation studies, and to facilitate rapid mapping with single gene resolution.

TwistDx Limited                
Release of TwistAmp™ exo RT - RT release date: 12th December - TwistDx are making available optimized reverse transcriptase (RT) kits to complement the current TwistAmp™ product line to permit a ‘one-step’ RNA amplification / detection reaction. For further information please contact: TwistDx Limited Minerva Building, Babraham Research Campus, Babraham, Cambridge UK CB22 3AT, T; +44 (0) 1223 496703, M; +44 (0) 7827 975 283, http://www.twistdx.co.uk

UNIConnect                
UNIFlow-MDx - The UNIFlow MDx LIMS has been designed to capture all the complex processes of in a molecular lab – even processes that are changing and evolving with the science.

Veridex LLC                
Using rare cell technology CellSearch, we have developed an automated assay for enriching, detecting and characterizing circulating multiple myeloma cells (CMMC) in the blood of patients diagnosed with Multiple Myeloma

View list and description of new products

About Molecular Medicine Tri-Conference
Molecular Medicine Tri-Conference -- the flagship event of CHI - has built this year's event around 5 scientific channels, encompassing 13 conferences, providing attendees more learning opportunities than ever before. Featured channels include diagnostics, chemistry, informatics, biologics, cancer and executive. We are looking to provide attendees a more in depth experience into each of these seven areas of research and development. As the need for better information, new technologies, improved strategies and competitive intelligence becomes ever more acute, this event provides compelling research insight into the future of molecular medicine. In 2012, we expect 3,000 attendees, 1,200 participating companies, 160 exhibitors, 120+ posters, and representatives from over 38 countries. http://www.TriConference.com

About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. http://www.chicorporate.com

Contact:
Tracey Fielding
Cambridge Healthtech Institute
Ph. 781-972-5429
tfielding(at)healthtech(dot)com

# # #

Read the rest here:
Plethora of New Products to be Showcased at 2012 Molecular Medicine Tri-Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (NASDAQ: VSTM - News) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced that the company will present at the 2012 Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology.” The presentation is on February 19, 2012 at 2:00pm PT at the InterContinental San Francisco Hotel.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM - News) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

View post:
Verastem to Present at Molecular Medicine Tri-Conference Symposium “Targeting Cancer Stem Cells in Oncology”

Read the original:
Alzheimers Neurons Created from Pluripotent Stem Cells

STEMEXPAND have been granted 3 mill. Euro from EU to pursue new methods to expand stem cells from umbilical cords. Stefan Karlsson, MD, Ph.D, Professor of Molecular Medicine and ass

Originally posted here:
Unlocking the Secrets of Blod Cell Therapy - Video